Literature DB >> 8362939

Diagnostic and treatment results from a southeastern academic center-based premenstrual syndrome clinic: the first year.

L Plouffe1, K Stewart, K S Craft, M S Maddox, J L Rausch.   

Abstract

OBJECTIVES: We attempted to ascertain the following: (1) the yield of a structured workup in a premenstrual syndrome clinic coordinated by a university-based gynecology department in the southeast, (2) referral patterns and care provided before consultation, and (3) therapeutic outcomes. STUDY
DESIGN: The first 100 women seen prospectively entered a uniform diagnostic and treatment protocol. Data analysis was performed with analysis of variance and confidence interval for a population proportion.
RESULTS: Thirty-eight women (95% confidence interval 28% to 48%) had premenstrual syndrome, 24 had premenstrual magnification syndrome (95% confidence interval 16% to 32%), 13 had an affective or other psychiatric disorder (95% confidence interval 6% to 20%). Only 44% of women previously given a diagnosis of premenstrual syndrome were found to have premenstrual syndrome. Overall, 84% of women with premenstrual syndrome and premenstrual magnification syndrome responded to treatment.
CONCLUSIONS: Too many women are still given the diagnosis of premenstrual syndrome without appropriate prospective documentation. Premenstrual magnification represents an important diagnostic category. Therapeutic responses to present treatments are encouraging.

Entities:  

Mesh:

Year:  1993        PMID: 8362939     DOI: 10.1016/0002-9378(93)90079-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Selective serotonin reuptake inhibitors for premenstrual syndrome.

Authors:  Jane Marjoribanks; Julie Brown; Patrick Michael Shaughn O'Brien; Katrina Wyatt
Journal:  Cochrane Database Syst Rev       Date:  2013-06-07

2.  Prescribing patterns in premenstrual syndrome.

Authors:  Katrina M Wyatt; Paul W Dimmock; Martin Frischer; Paul W Jones; Shaugn PM O'Brien
Journal:  BMC Womens Health       Date:  2002-06-19       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.